title: Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial.
authors: Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
authors: Lauren
authors: L
authors: Okon
authors: Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
authors: Misha
authors: M
authors: Rosenbach
authors: Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
authors: Michael
authors: M
authors: Krathen
authors: Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
authors: Mathew
authors: M
authors: Rose
authors: Department of Biostatistics at HUP, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
authors: Kathleen
authors: K
authors: Propert
authors: Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
authors: Joyce
authors: J
authors: Okawa
authors: Philadelphia Veterans Affairs Medical Center, Philadelphia, PA; Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA. Electronic address: werth@mail.med.upenn.edu.
authors: Victoria
authors: V
authors: Werth
mesh_terms: D000284:Administration, Oral; D001707:Biopsy, Needle; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D000077269:Lenalidomide; D008178:Lupus Erythematosus, Cutaneous / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D061214:Patient Safety; D011446:Prospective Studies; D012720:Severity of Illness Index; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D013792:Thalidomide; D000077269:Lenalidomide